Maze Therapeutics Reports Positive Phase 2 Trial Data

Maze Therapeutics has announced positive topline data from its Phase 2 HORIZON trial for MZE829. The trial demonstrated the first clinical proof-of-concept in patients suffering from broad AMKD, a significant milestone for the company. This success is expected to support the advancement of MZE829 into further clinical development. The results indicate promising therapeutic potential for the drug, offering hope for patients with this condition and bolstering Maze Therapeutics' pipeline.